Browse News
Filter News
Found 948 articles
-
Follow along as BioSpace keeps you up-to-date on the latest pharma and biotech layoffs.
-
Comprehensive Review Highlights Potential Benefits of Leukine® in Management of Gastrointestinal (GI) Adverse Events Associated with Immune Checkpoint Inhibitors (ICIs) in the Treatment of Cancer
4/18/2024
Partner Therapeutics, Inc. announced publication of a comprehensive review by Dougan et al. in Cancers summarizing the mechanistic rationale and pre-clinical and clinical data regarding the use of Leukine to manage gastrointestinal immune-related adverse events for patients taking immune checkpoint inhibitors for the treatment of cancer.
-
Active Pharmaceutical Ingredients Market Size to Increase USD 416.15 Billion By 2033
4/15/2024
The global active pharmaceutical ingredients market size was evaluated at USD 237.48 billion in 2023 and it is expected to increase around USD 416.15 billion by 2033 with a CAGR of 5.77% from 2024 to 2033.
-
Zevra Therapeutics Presents New Data on the Long-Term Safety and Efficacy of Arimoclomol as a Treatment for Niemann-Pick Disease Type C at the SIMD 45th Annual Meeting
4/15/2024
Zevra Therapeutics, Inc. today announced that new long-term real-world data from the arimoclomol expanded access program (EAP: NCT04316637) for the treatment of Niemann-Pick disease type C (NPC) was featured in an oral presentation during the Society for Inherited Metabolic Disorders (SIMD) 45th Annual Meeting taking place at the Sheraton/Le Meridien Charlotte Hotel Complex in Charlotte, NC, from April 14-17, 2024.
-
Federal funding and legislation spotlight women’s health opportunities and challenges.
-
Novo Nordisk and Ionis Pharmaceuticals unveiled promising respective data at the American College of Cardiology’s Annual Scientific Session, while Boehringer Ingelheim and Eli Lilly’s Jardiance missed the endpoint in a myocardial infarction study.
-
The American Association for Cancer Research has invited drug developers and investors to intermingle with the academics who typically attend its annual conference.
-
Flamingo Therapeutics Announces Participation in Upcoming Investor and Industry Conferences - April 04, 2024
4/4/2024
Flamingo Therapeutics announced its participation in the following upcoming investor and industry conferences.
-
Breakthroughs in Immunopsychiatry Take Center Stage at the Inflammatory Brain Disorders Conference
4/4/2024
The much-anticipated Inflammatory Brain Disorders Conference is back and being offered by Neuroimmune Foundation in collaboration with Neuroimmune Institute.
-
QIAGEN strengthens its portfolio for cancer research, showcasing latest product launches at AACR Annual Meeting 2024
4/3/2024
QIAGEN N.V. announced a series of new products to further enhance cancer research as well as to enable urine collection and stabilization as a new approach for liquid biopsy.
-
Labcorp to Present Diverse Portfolio of Precision Oncology Research at the Annual Meeting of the American Association for Cancer Research
4/2/2024
Labcorp, a global leader of innovative and comprehensive laboratory services, will present abstracts in the areas of immunology, cellular biology, genomics and liquid biopsy at the Annual Meeting of the American Association for Cancer Research® in San Diego.
-
While disease-modifying therapies largely steal the spotlight in Alzheimer’s drug development, several companies are working to solve this less-discussed but disruptive facet of the illness.
-
Lunit to Showcase 7 Studies at AACR 2024: Unveiling AI Innovations in HER2 Expression-Mutation Analysis and CNTN4 Biomarker Identification
4/1/2024
Lunit today announced the presentation of seven studies at the American Association for Cancer Research (AACR) 2024 Annual Meeting in San Diego, California, from April 5 to 10.
-
Charles River Laboratories Showcases Technology-Driven Capabilities at AACR 2024
4/1/2024
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that its industry-leading team of oncology experts will attend the American Association for Cancer Research (AACR) Annual Meeting.
-
Astellas' VYLOY™ (zolbetuximab) Approved in Japan for Treatment of Gastric Cancer
3/26/2024
Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that on March 26, 2024, Japan's Ministry of Health, Labour and Welfare (MHLW) approved VYLOY™ (zolbetuximab), an anti-claudin 18.2 (CLDN18.2) monoclonal antibody for patients with CLDN18.2 positive, unresectable, advanced or recurrent gastric cancer.
-
Biond Biologics Announces Presentation of BND-35, a Novel Anti-ILT3 Antibody for Remodeling the Tumor Microenvironment, at the American Association for Cancer Research (AACR) 2024 Annual Meeting
3/26/2024
Biond Biologics Ltd. is excited to announce that our BND-35 program has been selected for presentation at the esteemed American Association for Cancer Research (AACR) Annual Meeting, scheduled for April 5 - 10, 2024, in San Diego Convention Center, San Diego, CA, USA.
-
Ubiquitous potential, possible safety advantages and the recent growth of cell and gene therapy are driving investment in a different type of genetic editing.
-
Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a SPOTLIGHT Clinical Study of Briquilimab in Chronic Inducible Urticaria
3/19/2024
Jasper Therapeutics, Inc. today announced that the first patient has been dosed in Jasper’s Phase 1b/2a (SPOTLIGHT) clinical study of subcutaneous briquilimab for the treatment of CIndU.
-
Gilgamesh Pharmaceuticals Awarded $14 Million National Institute on Drug Abuse Grant to Advance Novel, Cardiac-Safe Ibogaine Analog for the Treatment of Opioid Use Disorder
3/14/2024
Gilgamesh Pharmaceuticals today announced that it has been awarded a multi-year $14 million grant from the National Institute on Drug Abuse (NIDA) to develop GM-3009, its novel, cardiac-safe ibogaine analog for the treatment of substance use disorders.
-
Intensity Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update
3/14/2024
Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS) announces full year 2023 financial results and provides a review of 2023 accomplishments and anticipated upcoming developments.